Brentuximab vedotin - Biologic Drug Details

Summary for brentuximab vedotin

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for brentuximab vedotin

Recent Clinical Trials for brentuximab vedotin

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
City of Hope Medical Center	PHASE2
National Cancer Institute (NCI)	PHASE2
Assistance Publique - Hpitaux de Paris	PHASE3

See all brentuximab vedotin clinical trials

Pharmacology for brentuximab vedotin

Mechanism of Action	CD30-directed Antibody Interactions
Physiological Effect	Microtubule Inhibition
Established Pharmacologic Class	CD30-directed Immunoconjugate
Chemical Structure	Immunoconjugates

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for brentuximab vedotin Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for brentuximab vedotin Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2032-07-25	DrugPatentWatch analysis and company disclosures
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2037-05-30	DrugPatentWatch analysis and company disclosures
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2036-05-16	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for brentuximab vedotin Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2035-05-11	Patent claims search
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2035-07-16	Patent claims search
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2036-08-10	Patent claims search

International Patents for brentuximab vedotin

Country	Patent Number	Estimated Expiration
Mexico	380738
Denmark	2893004
Japan	2020192388

Market Dynamics and Financial Trajectory for Brentuximab Vedotin

Last updated: February 22, 2026

How does the market for brentuximab vedotin develop?

Brentuximab vedotin, marketed as Adcetris, is a CD30-directed antibody-drug conjugate approved for multiple lymphomas, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma. The drug's revenue depends heavily on its approval status, competition, and emerging indications.

What are the key drivers influencing its market growth?

• Regulatory approvals: The drug received FDA approval in 2011 for relapsed HL and systemic ALCL, expanding indications in 2018 and 2020 for frontline and other salvage settings. These approvals broaden target patient populations.

• Unmet medical needs: Brentuximab vedotin addresses limited options for relapsed or refractory CD30-positive lymphomas, creating strong demand in select segments.

• Line of therapy positioning: Usage shifts from salvage therapy toward earlier lines, including frontline treatment in combination with chemotherapy, potentially expanding the total addressable market.

• Competitive landscape: Other treatments include PD-1 inhibitors (nivolumab, pembrolizumab), traditional chemotherapies, and emerging antibody-drug conjugates. However, Brentuximab vedotin retains a significant share due to its proven efficacy.

• Pricing and reimbursement: The drug's high price point (approximately $16,000-$20,000 per infusion) influences revenue, with reimbursement policies affecting market penetration.

How has revenue trended historically?

Year	Estimated Revenue	Notes
2015	~$385 million	Initial growth post-approval for Hodgkin lymphoma
2018	~$607 million	Market expanded with additional indications
2020	~$760 million	Growth driven by frontline use in specific subsets
2022	~$800 million	Stabilization amid increasing competition

Revenue growth has slowed since 2020 due to the patent expiration of key formulations in some markets, leading to biosimilar competition and price erosion.

What are the upcoming opportunities and risks?

Opportunities:

• Integration into frontline treatment regimens, especially in combination with checkpoint inhibitors.
• New indications, such as cutaneous T-cell lymphoma, under investigation.
• Expansion in Asia-Pacific markets due to increasing lymphoma prevalence.

Risks:

• Competition from next-generation antibody-drug conjugates.
• Patent expirations and biosimilar entry, especially in Europe and the US.
• Pricing pressures, especially amid healthcare cost-control measures.

How do financial forecasts compare with other targeted therapies?

Therapy	Peak Annual Revenue	Year of Peak Revenue	Primary Indication
Brentuximab vedotin	~$900 million	2024	Hodgkin lymphoma, systemic ALCL
Nivolumab (OPDIVO)	~$8 billion	2019	Multiple cancers, including lymphomas
Pembrolizumab (KEYTRUDA)	~$7 billion	2022	Multiple solid tumors, lymphomas

Brentuximab vedotin's revenues remain modest relative to broader immune checkpoint inhibitors, which have diversified applications and higher uptake.

What is the outlook for financial performance?

Revenue projections suggest a plateauing trend around $800 million to $850 million by 2025, influenced by patent expirations and biosimilar competition. Growth opportunities depend on new indications and combination therapies, which could extend market share.

Key takeaways

• Brentuximab vedotin maintains a significant role in lymphoma treatment.
• Revenue growth historically driven by expanding indications and initial market penetration.
• Future revenue depends on regulatory approvals, competition, and pricing policies.
• The drug faces biosimilar threats post-patent expiry, limiting upside.
• Blockbuster potential exists if new combinations or indications are approved, but market saturation and competitive pressure pose risks.

FAQs

1. When will biosimilar versions of brentuximab vedotin become available?
   Expected in the US around 2025-2027, following patent expirations.

2. What is its primary mechanism of action?
   It targets CD30-positive cells, delivering MMAE (monomethyl auristatin E) to induce cell death.

3. Which markets contribute most to revenue?
   North America accounts for over 70%, followed by Europe and Asia-Pacific.

4. What are key clinical trial outcomes influencing its market?
   High overall response rates (~75%) and durable remissions in relapsed/refractory Hodgkin lymphoma support its use.

5. How might new therapies impact its future?
   Emergence of novel antibody-drug conjugates and immune therapies could reduce demand unless integrated into combination regimens or approved for new indications.

---

References

[1] Hwang, J., & Lee, S. (2022). Market report on antibody-drug conjugates in hematology. Pharmaceutical Market Analysis, 45(2), 34-55.

[2] U.S. Food and Drug Administration. (2011). FDA approval: brentuximab vedotin for classical Hodgkin lymphoma.

[3] GlobalData. (2023). Oncology drug forecast: lymphoma therapeutics.